Laboratory Corporation of America Holdings (NYSE:LH) Q4 2019 Earnings Conference Call February 13, 2020 9:00 AM ET Company Participants Clarissa Willett - VP, IR Adam Schechter - President, CEO & Director Glenn Eisenberg - CFO & EVP Conference Call Participants Jack Meehan - Barclays Bank Lisa Gill - JPMorgan Chase & Co. Michael Newshel - Evercore ISI Kevin Caliendo - UBS Investment Bank Daniel Leonard - Wells Fargo Securities Ralph Giacobbe - Citigroup Rivka Goldwasser - Morgan Stanley Brian Tanquilut - Je ...

FOURTH QUARTER 2019 SUPPLEMENTAL FINANCIAL INFORMATION February 13, 2020 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS 1 This presentation of Laboratory Corporation of America Holdings (the "Company") contains forward-looking statements, including but not limited to statements with respect to estimated 2020 guidance and the related assumptions, the impact of various factors on operating and financial results, expected savings and synergies (including from the LaunchPad initiative and as a result ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 1-11353 LABORATORY CORP OF AMERICA HOLDINGS (Exact name of registrant as specified in its charter) | Delaware | | 13-3757370 ...

Laboratory Corporation of America Holdings (NYSE:LH) Q3 2019 Results Earnings Conference Call October 24, 2019 9:00 AM ET Company Participants Clarissa Willett - Vice President, Investor Relations David King - Chairman & Chief Executive Officer Glenn Eisenberg - Executive Vice President & Chief Financial Officer John Ratliff - CEO, Covance Drug Development Conference Call Participants Lisa Gill - JPMorgan Jack Meehan - Barclays Kevin Caliendo - UBS Kevin Ellich - Craig-Hallum Ralph Giacobbe - Citi Bill Quir ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 1-11353 LABORATORY CORP OF AMERICA HOLDINGS (Exact name of registrant as specified in its charter) | Delaware | | 13-3757370 | | - ...

Commission file number 1-11353 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact name of registrant as specified in its charter) Delaware 13-3757370 ...

Index UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K [X] Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2018 or [ ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ______ to ______ Commission file number - 1-11353 LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact name of registrant as specified in its charter) | Delaware | 13-37 ...